Amarillo, CytoPharm Intiates Enrollment For Hepatitis-C Study
Aim of trial is to reduce virologic relapse rate for patients who have completed the standard combination therapy
Amarillo (ABI) and CytoPharm have started the enrollment for a study of ABI's oral interferon-alpha lozenges, for chronic hepatitis-C virus infection.
The aim of the trial is to reduce the virologic relapse rate for patients who have completed the standard combination therapy, which consists of high dose injectable interferon-alpha and Ribavirin. Although most patients respond to the standard therapy, up to 50% of those with certain high-risk viral genotypes relapse after treatment.
In this study, a total of 165 patients who test positive for a high-risk hepatitis C viral genotype, will receive one of two different doses of human interferon-alpha or placebo given daily for 24 weeks. Full study enrollment is expected to complete by the end of the year.
The companies announced that CytoPharm is planning a study of oral interferon lozenges in the treatment of influenza, which is to be launched during the 2009/2010 flu season in Taiwan.
Related Insight
Suppliers Directory
NNIT - Full-Service IT Consultancy
With 15 years’ experience, NNIT understands the challenges businesses in the life sciences industry are facing. And we have the solutions.
Suppliers
BioTools - Advanced Scientific Analytical Instrumentation
BioTools develops and manufactures advanced scientific analytical instrumentation providing a range of unique products including Vibrational Circular Dichroism (VCD) and Raman Optical Activity (ROA) which are used in a range of chiral based applications and are extensively applied to determine chiral structures and function of both small and bio-molecules.
Suppliers
GOEBEL Instrumentelle Analytik - Complete Solutions in HPLC and UV/VIS Spectrophotometry
GOEBEL Instrumentelle Analytik offers complete solutions in HPLC and UV/VIS Spectrophotometry.
Suppliers
FPS Food and Pharma Systems Srl – Micronisation Systems and Containment Solutions
FPS Food and Pharma Systems Srl develops, manufactures and sells worldwide its own range of micronisation and containment solutions for the pharmaceutical, fine chemical, food and cosmetic industries.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Pipet Controller for Graduated, Volumetric and Blow-out Pipettes
Published by VITLAB®
White Papers
The Many Faces of Water Vapor
Published by Vaisala
White Papers
How to use ANOVA in Qlucore Omics Explorer
Published by Qlucore
White Papers
Company Brochure
Published by Unjo
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.